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A b s t r a c t
Introduction: Symptomatic dissections (SD) of cervical arteries are still a therapeutic problem. Although endovascular manage-
ment (EM) is currently a preferred method of treatment of SD, complications associated with this method of treatment in published 
reports are quite frequent (3–16%).
Aim: In this retrospective study we analyzed the results of EM with novel, double-mesh stent and protection systems (PS) for 
SD of the internal carotid (IC) or vertebral arteries (VA) that coexisted with hemodynamically significant stenosis or aneurysmatic 
dilatation of the dissected artery.
Material and methods: We evaluated the results of EM in 19 patients (men 15, median age: 55, range: 25–83), presenting 
with SD of the IC or VA with coexisting stenosis and/or aneurysmatic dilatation of the artery in segments C1-C5 of IC or V0-V4 of 
VA. Twelve patients had a stroke, 6 TIA, and 3 patients a headache and/or a neck pain with Horner syndrome. Stents and PS were 
tailored according to the location, length of dissection and coexisting stenotic or aneurysmatic lesions.
Results: There were no new strokes, in-hospital deaths or other serious morbidities during the procedure and postprocedural 
hospital stay. There were no fatalities during 6–40 months of follow-up. In control angiographies performed after interventions all 
patients demonstrated a patent target artery, complete coverage of the dissection and aneurysm by stents and no new lesions in 
the area of the previous dissection.
Conclusions: The results of this study indicate that EM of SD of IC and VA with the new stents and PS is safe and effective with 
good early and midterm results.
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S u m m a r y
Interventional treatment of carotid dissection is related, according to available literature, with a complication rate of up 
to 13%, and the incidence of occlusion in the C2-C5 segment of the carotid artery, after the use of stents dedicated to the 
treatment of intracranial aneurysms, can reach 10–18% (during 6–12 months of follow-up). In order to reduce the incidence 
of periprocedural complications, there were used protection systems (distal and proximal) and a new generation of flexible, 
double-mesh stents, allowing them to be introduced into the C4-C4 segment of the carotid artery or distal part of the verte-
bral artery. This study shows that the use of protection systems and the new double-mesh stents is a safe method with good 
early and midterm results (up to 40 months), with the effect of a flow-diverter stent.
Introduction
Carotid dissection is a relatively rare disorder and oc-
curs in 3 individuals out of 100,000 people per year [1–3]. 
It can be asymptomatic, but in 20% of patients, primarily 
those younger than 45 years, it results in cerebral events 
including strokes [4]. Most often dissection affects the 
internal carotid artery and is asymptomatic or associat-
ed with minor neurologic sequelae, such as cervical pain, 
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headache or Horner’s syndrome. Cerebral ischemic events 
are less common. In most cases the clinical course of ca-
rotid dissection is benign and symptoms resolve after 
pharmacological treatment. There is, however, a group of 
patients presenting with the signs of cerebral ischemia, 
which is usually due to embolization or significant steno-
sis of the dissected artery. These patients, regardless of 
the cause of dissection (associated with atherosclerosis, 
post-traumatic or iatrogenic), constitute a  large thera-
peutic challenge, especially if the dissection is localized 
in the cavernous (C4) or more distal segments of the in-
ternal carotid artery. Prior to introduction of endovascular 
management of such lesions, a full neurological recovery 
was only seen in a small percentage of patients [5]. Cur-
rently endovascular angioplasty and stenting is becoming 
a preferred method of treatments of carotid dissections 
[1–4, 6]. In a  large meta-analysis published in 2016, en-
dovascular management was found to be more effective 
than open surgical repair, with an acceptable frequency of 
serious adverse events [7, 8]. We analyzed our experience 
in the management of carotid and vertebral dissections to 
assess the effectiveness of stenting with use of new-gen-
eration stents and protection systems [9]. 
Aim
In this retrospective study we analyzed the efficacy 
and safety of treatment of symptomatic dissections of 
the internal carotid or vertebral arteries that coexisted 
with hemodynamically significant stenosis or aneurys-
matic dilatation of the dissected artery with use of the 
new-generation double-mesh stents (which can be used 
as a flow-diverting device excluding aneurysmatic dilata-
tion) with protection systems.
Material and methods
From May 2015 to February 2018 a  total of 19 pa-
tients (15 men, age range: 25–83, median: 55 years) were 
scheduled for endovascular treatment according to the 
algorithm in our hospital (Figure 1) with symptomatic 
dissection of the internal carotid or vertebral arteries 
with coexisting stenosis and/or aneurysmatic dilatation 
of the artery. The detailed inclusion and exclusion criteria 
are outlined in Table I.
Spontaneous dissection occurred in 16 patients (in-
cluding one with vertebral artery occlusion), traumatic 
disease in 2 patients and 1 in the iatrogenic mechanism.
In the analyzed patients, 12 (63%) patients suffered 
a  stroke (in 2 patients in the course of the dissection 
there was acute occlusion of the internal carotid artery 
(ICA), 6 (32%) patients had transient cerebral ischemia 
and in 3 (16%) there was head or neck pain with Horner 
syndrome symptoms).
As a preliminary imaging examination, an ultrasound 
examination was used, then the presence of lesions in all 
patients was confirmed by angiotomographic (CT) exam-
ination. The study was aimed at assessing the aorta and 
cervical arteries, including segments not available for the 
ultrasound examination.
The aortic arch was of type I in 12 cases, type II in 7, 
and type III in 2 patients. Bilateral stenosis of the carot-
id artery was found in 3 (16%), and occlusion was con-
firmed in 2 patients. Clinical characteristics of patients 
are given in Table II.
The primary endpoint was the proportion of patients 
who had new a stroke (different from the preprocedur-
al event or exacerbation of preprocedural stroke) or 
a stroke-related death. We included all types of strokes, 
both ipsi- and contralateral, as well as minor, major and 
fatal strokes. The secondary endpoint was the proportion 
of patients who had reocclusion or death that was not 
caused by the stroke. In addition, we assessed technical 
feasibility of endovascular repair of carotid and vertebral 
dissections, and also safety and feasibility of stent im-
Diagnosis CAD/VAD
Thromboembolic events (symptomatic 
during treatment) or size progression of 
pseudoaneurysm





Figure 1. Algorithm management of patients with dissection of carotid and vertebral arteries in our hospital
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plantation in the intracranial portion of the internal ca-
rotid artery.
Standard preprocedural management of patients 
comprised multidisciplinary assessment, including neu-
rological, neuroradiological and vascular consultations. 
Potential risks and benefits associated with the planned 
procedure were discussed with patients, and all of them 
gave their written informed consent. Details of the endo-
vascular procedure are described in the next part of this 
paper. Neurological assessment was performed at least 
once before the procedure and on postprocedural day 
1–2. Follow-ups were performed on the day of the pro-
cedure, and then after 1, 3, 6 and every 6 months (on an 
outpatient basis). Control CT angiographies or arteriogra-
phy were performed 3 or 6, 12 and 24 months after en-
dovascular repair. In all patients dual antiplatelet therapy 
was initiated 3–1 days before the day of the procedure. 
Periprocedurally, patients received unfractionated hepa-
rin at a dose of 100 U/kg. Patients were discharged home 
3-5 days (except for patients with acute stroke) after the 
procedure, with the recommendation of dual antiplatelet 
therapy (aspirin + clopidogrel or ticagrelor) for at least 
30 days, optimally for 3-6 months, or, in patients present-
ing with dissections which were longer than 60 mm, up 
to 12 months (Table III).
Endovascular techniques
The femoral artery was the preferred access site and 
it was used in 17 (89%) patients, while radial access was 
used in 2 patients. Stents and protection systems were 
tailored according to the specific patient and angioar-
chitecture of the dissection, particularly to its location, 
length and coexisting stenotic or aneurysmatic lesions 
(Table III). 
Usually, for the management of carotid dissections, 
we used the Precise (Cordis, Fremont, CA, USA), the Road-
Saver (Terumo, Tokyo, Japan) or the Carotid Wallstent 
(Boston Scientific, Natick, MA, USA) stents. As a protec-
tion system we used either the Mo.Ma Ultra 8F (Medtron-
ic, Minneapolis, MN, USA) proximal device and Cello 
catheter (Covidien, ev3 Endovascular, Inc., Plymouth, 
MN, USA), or distal protection filters, such as the Spider-
FX Embolic Protection Device (Covidien, ev3 Endovascu-
lar, Inc., Plymouth, MN, USA) and the Emboshield NAV6 
Embolic Protection System (Abbott Vascular, Abbott Park, 
IL, USA). In the case of distal lesions or large aneurysms 
of a  cervical portion of the carotid artery we used the 
following stents: the RoadSaver and the Leo-Baby (Balt 
Extrusion, France) self-expanding stents. Since a stenosis 
associated with dissection is simply the result of a false 
lumen and intimal flap, self-expanding closed-cell stents 
(RoadSaver or Leo-Baby stents) are usually sufficient to 
address lesions located in the upper part of the neck. We 
used protection systems in all patients. 
Table I. Inclusion and exclusion criteria for pa-
tients with dissection
Inclusion criteria
1.  Dissection in the common, internal or vertebral carotid artery 
with significant stenosis and/or pseudoaneurysm with neurolog-
ical symptoms as a result of hypoperfusion or ischemia in the 
thromboembolic mechanism
2.  Progression of stenosis within the dissection or a size of the false 
aneurysm found in the control imaging studies (ultrasound exam-
ine, angiotomography (CT), digital subtraction angiography (DSA))
3.  Recurrent thromboembolic events with a starting point in the 
dissection located in the common, internal carotid artery (in the 
segment from C1 to C5) or in the vertebral artery in segments 
from V0 to V3, occurring despite the optimal clotting therapy
4.  The technical possibility of a common, internal or vertebral ca-
rotid angioplasty procedure
Exclusion criteria
1.  The condition of the patient’s limbs or the presence of an accom-
panying disease in which a revascularization procedure would be 
inappropriate; an accompanying disease which is a contraindica-
tion to the procedure
2.  Extensive ipsilateral or disabling stroke, ischemic ipsilateral 
stride progressing to hemorrhagic one within 60 days, or de-
creased brain, dementia, multiple lacunar infarct
3.  Healing dissection, dissection without critical stenosis and no 
signs of progression or asymptomatic dissection during antico-
agulation treatment
4.  Recognized allergy or hypersensitivity to acetylsalicylic acid, 
clopidogrel and ticagrelor
5.  Hypersensitivity to contrast agents that do not give satisfactory 
treatment before surgery
6.  Pregnant and reproductive women who do not use effective con-
traception
7.  Target change in a chronic total occlusion of considerable length 
and/or a continuous, heavy calcification or very winding com-
mon and internal carotid arteries
8.  An active inflammatory process at the site of the planned in-
jection
Table II. Demographic, clinical and diagnostic data, 
and endovascular interventions (n = 19)
Parameter N (%) or mean ± SD
Age [years] 55.7 ±16.6
Patient older than 80 years 3 (16)
Male patients 15 (79)
Risk factors:
Stable coronary heart disease 4 (21)
Arterial hypertension 6 (32)
Diabetes mellitus 3 (16)
Dyslipidemia 7 (37)
Cigarette smoking 3 (16)
Renal impairment 2 (10)
Peripheral artery disease 2 (10)
History of percutaneous coronary 
angioplasty
4 (21)
History of coronary artery bypass graft 
surgery
2 (10)
History of myocardial infarction 2 (10)
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Results
Eighteen patients presented with dissections of the 
internal carotid artery and 1 patient with a dissected ver-
tebral artery. Length of lesions varied from 22 to 156 mm 
(mean: 60.1 ±38.7 mm). In 16 patients dissections co-
existed with aneurysmatic dilatation of the artery, with 
maximal diameter of such an aneurysm 3–18 mm 
(mean: 6.6 ±2.6 mm). Details are presented in Table III. 
Out of these 19 patients, in 8 (42%) patients, consid-
ering morphology of the lesion and overall clinical pic-
ture, we performed endovascular interventions without 
an attempt to treat them conservatively (this included 
2 patients in whom we performed urgent endovascular 
procedures due to acute occlusion of the internal carotid 
artery, other patients were managed as quick as possi-
ble, usually within 7–30 days from the first symptoms). 
The remaining 11 (58%) patients were initially managed 
conservatively and the decision to address the dissection 
endovascularly resulted from clinical worsening due to: 
recurrent cerebral embolism in 6 patients, progression of 
stenosis in 3 patients and progression of pseudoaneu-
rysm in 2 of them (Figure 2). 
In 8 patients it was possible to repair the dissection 
using only one stent, in 10 patients we used two stents 
and in 1 patients three stents (Table III). 
In 8 patients, proximal protection was used, in 6 pa-
tients Mo.Ma (Medtronic, Minneapolis, MN, USA), in 2 the 
Cello system (Covidien, ev3 Endovascular, Inc., Plymouth, 
MN, USA), in 9 patients the SpiderFX distal protection 
system Embolic Protection Device (Covidien, ev3 En-
dovascular, Inc., Plymouth, MN, USA), and in 2 the Em-
boshield NAV6 Embolic Protection System (System (Ab-
bott Vascular, Abbott Park, IL, USA). Out of 19 patients in 
whom a protection system was used, in 7 of them filters 
captured embolic debris (in 3 patients a lot of debris).
When the proximal protection system was used, 
mean duration of the proximal protection was 9.26 ±2.3 
min, and all patients well tolerated the protection. In 
Table III. Location of dissections











1 L ICA 99 C1-C2 25 Yes S, RS A, C 6 U, CT
2 R ICA 90 C1 22 Yes S, RS A, C 6 U
3 R ICA 85 C1-C2 27 Yes E, RS A, C 6 U
4 R ICA 85 C1 25 Yes E, RS A, C 3 C
5 L ICA 100 (A) C3 40 Yes M, P ,P , CW A, C 12 C, D
6 L ICA 99 C1-C2 59 Yes S, RS, CW A, C 12 C, D
7 L ICA 90 C1-C5 106 Yes M, P, LB A, C 12 C, D
8 L ICA 99 C1-C3 52 Yes M, P, P A, C 6 U, C
9 R ICA 80 C3 32 Yes C, P, P A, C 6 C
10 R ICA 99 C1-C3 52 Yes S, RS A, C 6 U, D
11 R ICA 100 (A) C1-C3 72 Yes S, RS A, C 12 U, D
12 L VA 70 V3 and V1 31 and 27 Yes S, LB, RS A, C 6 C, D
13 R ICA 99 C1-C3 99 No M, RS 2× A, C 12 D, C
14 R ICA 40 C3 28 Yes M, RS A, T 6 C, D
15 L ICA 99 C1-C3 90 No M, RS 2× A, T 12 C, D
16 R ICA 99 C-C3 80 Yes S, LB, RS A, T 6 C, D
17 L ICA 60 C1, C3 60 Yes S, RS 2× A, T 6 C
18 R ICA 50 C2-C3 28 Yes S, RS A, T 6 C, D
19 L ICA 100 (A) C1-C4 106 Yes C, RS 2× A, T 12 C, D
Loc. of DIS – location of dissection, ICA – internal carotid artery, VA – vertebral artery, C1 – cervical segment of ICA, C2 – petrous segment of ICA, C3 – lacerum segment 
of ICA, C5 – clinoid segment of ICA, V1 – preforaminal segment of vertebral artery, V3 – suboccipital part of vertebral artery, DIS – dissection, PA – pseudoaneurysm, 
DAPT – dual antiplatelet therapy. (A) – acute occlusion with neurologic symptoms, device – protection system, type of stents (S – SpiderFX Embolic Protection Device, 
E – Emboshield NAV6 Embolic Protection System, M – Mo.Ma 8F, C – Cello, P – Precise stent, CW – Carotid Wallstent stent, RS – RoadSaver stent, LB – Leo-Baby), 
A – acetylsalicylic acid, C – clopidogrel, T – ticagrelor, type of control (U – ultrasound, C – CT angio, D – angiography).
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15 patients presenting with pseudoaneurysms, a total of 19 
double-mesh RoadSaver stents were implanted as flow-di-
verting devices (Table III), in order to cover the entire dis-
section and exclude blood flow from aneurysmatic lesions. 
There were no technical failures or adverse events as-
sociated with endovascular procedures. Also, there were 
no in-hospital deaths, new neurological events or other 
serious morbidities during the procedure and postproce-
dural hospital stay. Patients presenting with neurological 
deficits prior to intervention improved after endovas-
cular repair and this improvement was maintained at 
hospital discharge. There were no fatalities during 6–40 
months of follow-up. 
In the follow-up imaging tests, the correct apposition, 
complete coverage of the lesions, and full closure of the 
pseudoaneurysm (effect of the flow-diverter stent) were 
confirmed. 
Discussion
Conservative management of dissected carotid arter-
ies, comprising anticoagulation or antiplatelet therapy, 
results in quite good clinical outcomes. Although report-
ed recanalization rates with hemodynamically sufficient 
flow through the affected artery are at the level of 50% 
and reocclusions are frequent [10, 11], Kremer et al. re-
ported a 0.7% annual rate of recurrent ipsilateral stroke 
in patients with a permanently occluded dissected carot-
id artery and 0.3% in patients with a recanalized artery 
[12]. In the CADISS study that evaluated results of treat-
ment in 250 patients with cervical dissection, there was 
2% incidence of recurrent strokes [13]. Multiple dissec-
tions and dissection of the carotid artery were associated 
with poorer prognosis [14, 15].
Yet, a  failed medical treatment in selected patients 
is an indication for endovascular repair of the dissection 
[16–18]. It is currently assumed that standard indications 
for endovascular intervention comprise recurrent isch-
emic events, high-grade stenosis within dissection with 
significantly limited flow, expanding pseudoaneurysm 
associated with dissection and occlusion or high-grade 
stenosis of the contralateral internal carotid artery. Still, 
endovascular management of cervical dissections can be 
associated with high rates of serious adverse events. The 
incidence of these complications in published reports 
was as high as 3–16% [7, 18, 19]. Adverse events were 
less frequent in patients with traumatic dissections [19]. 
Rates of serious adverse events associated with endo-
vascular management of cervical dissection are signifi-
cantly higher than those in patients undergoing carotid 
or vertebral artery stenting for atherosclerotic stenosis. 
Interestingly, although cerebral embolism is the most fre-
quent cause of serious adverse events associated with 
cervical dissections, protection systems were used rather 
infrequently during endovascular repair of these lesions. 
In the study published by Cohen et al. only 13% of the pa-
tients were managed under distal protection [20]. Malek 
et al. [21] did not use protection at all, and in the work 
of Edgell et al. it was emphasized that the introduction of 
the protection system may lead to progression of dissec-
tion [22]. In our study, the system of protection was used 
in all patients, and in 42% of the patients the proximal 
protection system (PSP) was used.
In contrast to the above-cited studies, in our patients 
endovascular repair of the dissections was uneventful.
Martinelli et al. obtained similarly good results in 
a study where all patients were treated endovascularly 
under distal protection [23]. In our work both types of 
protection were used: proximal and distal. The PSP is the 
system of choice, protecting cerebral tissue from embo-
lization from the very beginning of the procedure, and 
19 patients with dissection of carotid or vertebral artery
Successful stenting procedure in 19 patients
11 patients to managed conservatively8 patients managed endovascularly  
with stenting due to:
– 2 acute ischemia cerebri
– 5 reccurent TIA
–  1 dissection with critical stenosis with 
contralateral acute stroke
Patients converted to endovascular  
treatment due to:
–  progression of stenosis with symp-
toms – 3 patients
–  cerebral embolization during anti-
thrombolitic treatment – 6 patients
–  progression of pseudoaneurysm –  
2 patients
Figure 2. Treatment plan and qualification for interventional treatment of patients with carotid or vertebral 
arteries dissection
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was used mainly in the case of long lesions, including 
2 and more segments. In other cases, a distal protection 
was used, mainly the Spider system (Medtronic), which 
allows for the use of any guidewire. In both groups of 
patients, no neurological events occured, neither during 
hospital stay nor during follow-up.
Additionally, in our work, in 15 patients we used 
a new generation of double-mesh stents. Their unique-
ness, in comparison with previously used stents, includ-
ed low profile and high flexibility, allowing the device to 
be inserted into segments previously unavailable for oth-
er types of stents. Also, such a double mesh stent acted 
as a flow-diverter stent allowing a thrombotic closure of 
the aneurysm. Other authors reported the use of other 
stents in the segments C2-C5 [7, 24]. This translated 
into a relatively high percentage of reocclusions of these 
stents, due to their low radial force, and unpredictable 
effects of geometry changes of these stent that were 
dedicated to the treatment of lesions in the arteries, 
which are not subject to shape changes [7, 24]. The used 
RoadSaver stents, as stents dedicated to the treatment 
of atherosclerotic lesions, had adequate radial force, and 
additionally, due to the dense braid mesh, they exhibit 
the function of a flow-diverter stent, which allows them 
to be used in lesions with coexisting aneurysm [25]. In 
our material, all patients had occluded aneurysms and 
patent stents during follow-up to 40 months.
The results of our study, despite the limitations (small 
number of patients, retrospective study), are encouraging. 
During the observation period stents were patent, despite 
their considerable length, and patients were free from 
neurological symptoms. In cases when in spite of optimal 
conservative therapy, neurological symptoms are present, 
or when there is hypoperfusion of the brain, endovascular 
treatment may be a  reasonable alternative, especially in 
high-risk patients. The use of a new generation of stents, 
with the property of flow-diverter stents and protection 
systems, can minimize the occurrence of adverse events 
during the procedure, which until now has been the most 
serious limitation of endovascular procedures. In addition, 
antiplatelet therapy reduces the risk of peri- and postopera-
tive events, reducing the frequency of anticoagulant thera-
py and avoiding related complications [23].
Conclusions
Anticoagulant therapy is still the treatment of choice 
in patients with dissection of cervical arteries, especially 
in the asymptomatic group. In the cases when anticoag-
ulation is contraindicated or there are recurrent ischemic 
episodes, despite appropriate medical treatment, en-
dovascular treatment with the use of novel stents, and 
protection systems (especially proximal), provides good 
short- and midterm results. Despite small number of pa-
tients, our data suggest that endovascular treatment in 
such cases can be considered as an alternative treatment.
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